Insights In Gastrointestinal Cancers 2021

This book offers a summary and discussion of the advances of inflammation and infection in various cancers. The authors cover the classically known virus infections in cancer, novel roles of other pathogens (e.g. bacteria and fungi), as well as biomarkers for diagnosis and therapy. Further, the chapters highlight the progress of immune therapy, stem cells and the role of the microbiome in the pathophysiology of cancers. Readers will gain insights into complex microbial communities, that inhabit most external human surfaces and play a key role in health and disease. Perturbations of host-microbe interactions often lead to altered host responses that can promote cancer development. Thus, this book highlights emerging roles of the microbiome in pathogenesis of cancers and outcome of therapy. The focus is on mechanistic concepts that underlie the complex relationships between host and microbes. Approaches that can inhibit infection, suppress chronic inflammation and reverse the dysbiosis are discussed, as a means for restoring the balance between host and microbes. This comprehensive work will be beneficial to researchers and students interested in infectious diseases, microbiome, and cancer as well as clinicians and general physiologists.

Gastrointestinal cancers are among the most prevalent malignancies worldwide, with high rate of global cancer incidence and cancer-related death. Gastrointestinal cancers include esophageal cancer, gastric cancer, colorectal cancer, pancreatic cancer, and liver cancer, which all, except the last one, are covered in this volume. The fourth volume of the “Interdisciplinary Cancer Research” series, entitled “Gastrointestinal Cancers: An Interdisciplinary Approach” publishes comprehensive volumes on mechanisms of gastrointestinal cancers and novel immunotherapy opportunities and presents the most updated and peer-reviewed chapters on gastrointestinal cancers therapy. This interdisciplinary series is of special value to researchers working on cell biology, immunology, biochemistry, genetics, and practitioners working on oncology and gastroenterology. This is the main concept of Cancer Immunology Project (CIP), which is a part of Universal Scientific Education and Research Network (USERN). This interdisciplinary book will be of special value for researchers, oncologists, and gastroenterologists who wish to extend their knowledge on gastrointestinal cancers.

This book covers state-of-the-art topics covering evidences indicate that the gut microbiota can be harnessed for cancer prevention as well as to modulate the efficacy of chemotherapy and immunotherapy. This book includes: 1) characterization of the dysregulated microbiome in gastrointestinal cancers (Chapters 1-6); 2) the molecular mechanism of action of gut microbiota via microbial metabolites and direct interaction with host cancer or immune cells (Chapters 7-11); 3) key methodologies for studying the role of gut microbiota in cancers (Chapters 12-13); and 4) the potential application of gut microbes for the prevention and treatment of gastrointestinal cancers (Chapters 14-17). The contributors are international experts in molecular and cellular biology, microbiology, metabolomics, bioinformatics and physician scientists to provide in-depth reviews of this subject. This book provides a rich resource of information on this important topic for graduate students, basic researchers and physicians.

Molecules Engineered Against Oncogenic Proteins and Cancer A comprehensive review of the latest molecular advances in cancer treatment Featuring 91 total small molecule kinase/KRAS inhibitors, 80 of which are FDA-approved, Molecules Engineered Against Oncogenic Proteins and Cancer documents the recent scientific advances that have transformed one of medicine’s most challenging areas—cancer treatment. Most of these inhibitors specifically block oncogene-induced carcinogenic proteins with results that have dramatically advanced the treatment of cancer. In addition, the structural formulas of more than 100 kinase/KRAS inhibitors in clinical trials are presented. With a very well-known chemist as an author, Molecules Engineered Against Oncogenic Proteins and Cancer includes information on: Each molecule’s structure, function of the kinase target and relevance to cancer, the drug discovery process, and molecular details of drug action Mutated protein kinases as oncoproteins and targets for inhibition, along with the details of discovery for each antitumor antikinase agent History of oncoprotein inhibitors and their role in advancing the treatment and understanding of cancer The discovery process as a whole, effective strategies for innovation, ongoing challenges, and a glimpse of the future of the field Combining the most significant recent discoveries in a unique and useful way, Molecules Engineered Against Oncogenic Proteins and Cancer is an essential resource for researchers and students in bioscience, medicine, chemistry, and oncology as well as for those at industrial companies involved in therapeutic discovery.